Evidence map›Paper›PMID 28411252›Full record

Trial reportHaematologica2017

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Wendy B C Stevens, Matias Mendeville, Robert Redd, Andrew J Clear, Reno Bladergroen, Maria Calaminici, Andreas Rosenwald, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard and 18 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Benign and malignant tumors in Rubinstein-Taybi syndrome.American journal of medical genetics. Part A · 2018
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Follicular lymphoma microenvironment: insights provided by single-cell analysis.Journal of clinical and experimental hematopathology : JCEH · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 16 institutions in 7 countries.

Wendy B C StevensDepartment of Hematology, Radboudumc, Nijmegen, the Netherlands wendy.stevens@radboudumc.nl.
Matias MendevilleDepartment of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
Robert ReddDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew J ClearCentre for Haemato-Oncology, Barts Cancer Institute, University of London, UK.
Reno BladergroenDepartment of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
Maria CalaminiciCentre for Haemato-Oncology, Barts Cancer Institute, University of London, UK.
Andreas RosenwaldInstitute of Pathology, Comprehensive Cancer Center Mainfranken, University of Würzburg, Germany.
Eva HosterDepartment of Medicine III, University Hospital Grosshadern, Munich, Germany.
Wolfgang HiddemannDepartment of Medicine III, University Hospital Grosshadern, Munich, Germany.
Philippe GaulardDepartment of Pathology and Inserm U955, Hôpital Henri Mondor, University Paris-Est, Créteil, France.
Luc XerriDépartement de Biopathologie, Institut Paoli-Calmettes, Marseille, France.
Gilles SallesService d'Hématologie,Hospices Civils de Lyon & Université Claude Bernard Lyon-1, UMR CNRS 5239, France.
Wolfram KlapperInstitute of Pathology, University of Schleswig-Holstein, Kiel, Germany.
Michael PfreundschuhMedical Clinic I, Saarland University Hospital, Homburg, Germany.
Andrew JackHaematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
Randy D GascoyneDepartment of Pathology & Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, CA, USA.
Ranjana AdvaniDepartment of Hematology, Stanford University School of Medicine, CA, USA.
Eva KimbyDepartment of Medicine, Division of Hematology, Karolinska Institute, Stockholm, Sweden.
Birgitta SanderDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
Laurie H SehnDepartment of Pathology & Medical Oncology, Centre for Lymphoid Cancer, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
Anton HagenbeekDepartment of Hematology, Academic Medical Center, Amsterdam, the Netherlands.
John RaemaekersDepartment of Hematology, Radboudumc, Nijmegen, the Netherlands.
John GribbenCentre for Haemato-Oncology, Barts Cancer Institute, University of London, UK.
Marie José KerstenDepartment of Hematology, Academic Medical Center, Amsterdam, the Netherlands.
Bauke YlstraDepartment of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
Edie WellerDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Daphne de JongDepartment of Pathology, VU University Medical Center, Amsterdam, the Netherlands.
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLQueen Mary University of London · GBAmsterdam UMC Location University of Amsterdam · NLBC Cancer Agency · CADana-Farber Cancer Institute · USKarolinska Institutet · SEStanford University · USChristian-Albrechts-Universität zu Kiel · DEComprehensive Cancer Center Mainfranken · DEInserm · FRInstitut Paoli-Calmettes · FRRadboud University Medical Center · NLRadboud University Nijmegen · NLSaarland University · DESt James's University Hospital · GBUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In follicular lymphoma, studies addressing the prognostic value of microenvironment-related immunohistochemical markers and tumor cell-related genetic markers have yielded conflicting results, precluding implementation in practice. Therefore, the Lunenburg Lymphoma Biomarker Consortium performed a validation study evaluating published markers. To maximize sensitivity, an end of spectrum design was applied for 122 uniformly immunochemotherapy-treated follicular lymphoma patients retrieved from international trials and registries. The criteria were: early failure, progression or lymphoma-related death <2 years

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntigens, CDAntigens, Differentiation, MyelomonocyticAntineoplastic Combined Chemotherapy ProtocolsBiomarkersCD163 AntigenCD8 AntigensChromosomes, Human, Pair 18CyclophosphamideDoxorubicinEnhancer of Zeste Homolog 2 ProteinHumansLymphoma, FollicularPrednisonePrognosisReceptors, Cell SurfaceAntibodies, Monoclonal, Murine-DerivedAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD163 AntigenCD8 AntigensCyclophosphamideDoxorubicinEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPrednisoneR-CHOP protocolReceptors, Cell SurfaceRituximabVincristine

Identifiers

PMID28411252
PMCPMC6643731
OpenAlexW2606755458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.